The serum levels of PARK7 are significantly increased in patients with pancreatic cancer compared to those in healthy tissues, and this elevation is associated with tumor differentiation and reduced survival of patients with pancreatic cancer [78]. This evidence concerns the gene PARK7 and neoplasm.